Amanda F Cashen

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. doi request reprint Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    Amanda F Cashen
    Washington University School of Medicine, St Louis, MO, USA
    J Clin Oncol 28:556-61. 2010
  2. ncbi request reprint Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine
    Amanda F Cashen
    Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, St Louis, Missouri, USA
    Am J Hematol 81:543-5. 2006
  3. ncbi request reprint AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent
    Amanda F Cashen
    Washington University School of Medicine, Division of Oncology, 660 South Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA
    Future Oncol 3:19-27. 2007
  4. ncbi request reprint Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Amanda F Cashen
    Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, 660 S Euclid Ave, Box 8007, St Louis, MO 63110, USA
    Cancer Chemother Pharmacol 61:759-66. 2008
  5. ncbi request reprint Therapy of relapsed Hodgkin lymphoma
    Amanda F Cashen
    Division of Oncology, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    Blood Rev 21:233-43. 2007
  6. ncbi request reprint Salvage regimens for Hodgkin lymphoma
    Amanda F Cashen
    Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Adv Hematol Oncol 6:517-24. 2008
  7. ncbi request reprint A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma
    Amanda Cashen
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:1253-61. 2008
  8. pmc Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation
    Jacob P Smeltzer
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 17:1646-52. 2011
  9. ncbi request reprint Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
    Iskra Pusic
    Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:1045-56. 2008
  10. ncbi request reprint Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
    Geoffrey L Uy
    Washington University School of Medicine, Division of Oncology, 660 S Euclid Avenue, Campus Box 8007, St Louis, Missouri 63110, USA
    Expert Opin Biol Ther 8:1797-804. 2008

Collaborators

Detail Information

Publications20

  1. doi request reprint Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    Amanda F Cashen
    Washington University School of Medicine, St Louis, MO, USA
    J Clin Oncol 28:556-61. 2010
    ..We investigated the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older patients with AML...
  2. ncbi request reprint Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine
    Amanda F Cashen
    Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, St Louis, Missouri, USA
    Am J Hematol 81:543-5. 2006
    ..He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine...
  3. ncbi request reprint AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent
    Amanda F Cashen
    Washington University School of Medicine, Division of Oncology, 660 South Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA
    Future Oncol 3:19-27. 2007
    ..In Phase II trials, mobilization with the combination of AMD3100 and granulocyte colony-stimulating factor (G-CSF) results in the collection of more progenitor cells than G-CSF alone...
  4. ncbi request reprint Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Amanda F Cashen
    Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, 660 S Euclid Ave, Box 8007, St Louis, MO 63110, USA
    Cancer Chemother Pharmacol 61:759-66. 2008
    ..In this study, pharmacokinetics (PK) of decitabine administered as a 3-h intravenous infusion of 15 mg/m2 every 8 h for 3 days (cycles repeated every 6 weeks) was evaluated in patients with MDS or AML...
  5. ncbi request reprint Therapy of relapsed Hodgkin lymphoma
    Amanda F Cashen
    Division of Oncology, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    Blood Rev 21:233-43. 2007
    ..New salvage regimens that incorporate gemcitabine, vinorelbine, rituximab, and/or monoclonal antibodies against CD30 are being investigated...
  6. ncbi request reprint Salvage regimens for Hodgkin lymphoma
    Amanda F Cashen
    Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Adv Hematol Oncol 6:517-24. 2008
    ....
  7. ncbi request reprint A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma
    Amanda Cashen
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:1253-61. 2008
    ..The PK of plerixafor in this patient population was similar to that previously seen in healthy volunteers. The regimen was generally safe and well tolerated...
  8. pmc Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation
    Jacob P Smeltzer
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 17:1646-52. 2011
    ..2 (confidence interval [CI] 1.1-9.0, P = .03). Pre-ASCT FDG-PET scans predict EFS in patients with relapsed cHL patients treated with modern salvage/ASCT therapy and warrant prospective evaluation...
  9. ncbi request reprint Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
    Iskra Pusic
    Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:1045-56. 2008
    ..Patients who fail initial mobilization are more likely to fail remobilization. These findings suggest that there is a need for more effective first-line mobilization agents...
  10. ncbi request reprint Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
    Geoffrey L Uy
    Washington University School of Medicine, Division of Oncology, 660 S Euclid Avenue, Campus Box 8007, St Louis, Missouri 63110, USA
    Expert Opin Biol Ther 8:1797-804. 2008
    ....
  11. pmc A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
    Geoffrey L Uy
    Division of Oncology, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA
    Blood 119:3917-24. 2012
    ..We conclude that the addition of plerixafor to cytotoxic chemotherapy is feasible in AML, and results in encouraging rates of remission with correlative studies demonstrating in vivo evidence of disruption of the CXCR4/CXCL12 axis...
  12. pmc A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    Todd A Fehniger
    Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 118:5119-25. 2011
    ..This trial is registered at www.ClinicalTrials.gov as NCT00540007...
  13. ncbi request reprint Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
    Mike G Martin
    Section of Leukemia and Bone Marrow Transplantation, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri, USA
    Am J Hematol 84:733-7. 2009
    ..The patients who received G-CSF concurrently with chemotherapy had improved outcomes. Am. J. Hematol., 2009. (c) 2009 Wiley-Liss, Inc...
  14. pmc A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
    John S Welch
    Division of Oncology, Department of Internal Medicine, Washington University, St Louis, Missouri
    Am J Hematol 89:E103-8. 2014
    ..Am. J. Hematol. 89:E103-E108, 2014. © 2014 Wiley Periodicals, Inc. ..
  15. pmc Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen
    Shivaprasad Manjappa
    Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
    Biol Blood Marrow Transplant 20:46-52. 2014
    ....
  16. pmc A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    Todd A Fehniger
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO, USA
    Blood 117:1828-33. 2011
    ..HD lenalidomide has evidence of clinical activity as initial therapy for older AML patients, and further study of lenalidomide in AML and MDS is warranted. This study is registered at www.clinicaltrials.gov as #NCT00546897...
  17. ncbi request reprint A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
    Mike G Martin
    Washington University School of Medicine, Saint Louis, Missouri 63110, USA
    Am J Hematol 84:560-4. 2009
    ..This regimen appeared to offer a PR + CR rate and median DOR somewhat similar to what has been reported with the 7-day subcutaneous regimen; however, OS was shorter...
  18. pmc 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation
    Amanda F Cashen
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    J Nucl Med 52:386-92. 2011
    ..18)F-FDG PET may also be predictive of outcome when performed during the treatment course of DLBCL, but robust prospective studies and standardization of (18)F-FDG PET interpretation in this setting are lacking...
  19. ncbi request reprint Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells
    Amanda F Cashen
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Drugs Today (Barc) 45:497-505. 2009
    ..This review will summarize clinical trials, current use for autologous stem cell mobilization and future directions for plerixafor...
  20. ncbi request reprint Cytokines and stem cell mobilization for autologous and allogeneic transplantation
    Amanda F Cashen
    Division of Oncology, 660 South Euclid Ave, Washington University, St Louis, MO 63110, USA
    Curr Hematol Rep 3:406-12. 2004
    ..Here we review recent studies that advance our understanding of the biology of stem cell mobilization. We then discuss cytokines in current use and in development for mobilization of autologous and allogeneic peripheral blood stem cells...